NCT04521764
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with ER/PR+, HER2-nega breast cancer must have progressed through at least one prior cytotoxic regimen for advanced disease & no longer be candidates for standard endocrine therapy (including combination therapy that includes palbociclib or everolimus); Patients with HER2+ breast cancer must have received or no longer be candidates for standard HER2 directed therapy (i.e., Herceptin/trastuzumab, Perjeta/pertuzumab, Kadcyla/trastuzumab emtansine); Patients with triple negative breast cancer must have progressed through at least one prior cytotoxic regimen for advanced disease
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT04521764